Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    WRAIR, Duke Scientists Find Evidence of Monoclonal Antibody Activity Against Malaria

    By Global Biodefense StaffMarch 5, 2021
    little mosquitoes hatching out of eggs
    Share
    Facebook LinkedIn Reddit Email

    Scientists at Walter Reed Army Institute of Research, in a collaboration with Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

    The study, led by Dr. Sheetij Dutta, chief of the Structural Vaccinology Laboratory at WRAIR, showed that mAbs such as CIS43 were most effective in a culture-based assay that measured malaria parasites’ ability to infect a human liver cell, while another mAb 317 showed the best activity in a mouse infection model.

    The “difference in assay outcomes for mAbs could reflect distinct sites on the circumsporozoite protein that can be exploited for developing improved vaccines,” Dutta noted.

    Despite decades of malaria vaccine research, current vaccine candidates have shown low efficacy in field trials conducted in several countries in Africa. Many researchers from around the world have now focused their attention on using monoclonal antibodies against the circumsporozoite protein of the parasite.

    Unlike vaccines, where protective responses can take multiple doses and many months to develop, mAbs may offer months of protection immediately after administration of a single injectable dose and can be developed at a fraction of the cost of developing new drugs.

    Army Col. Jason Regules, MD, director of WRAIR’s Malaria Biologics Branch, added, “this was a critical study and will help to guide our future work in isolating monoclonal antibodies of unique specificity and activity from ongoing clinical trials of the FMP013 and FMP014 malaria vaccines that were developed at the WRAIR, in collaboration with our malaria research partners.”

    Malaria, spread by infectious mosquitoes, causes over 200 million cases and kills hundreds of thousands of people every year, with a disproportionate allocation of morbidity and mortality distributed amongst children and pregnant women living in the most impoverished and resource-limited areas of the world. Malaria-naïve travelers to malaria-endemic regions must employ anti-malarial countermeasures or also be at risk of grave illness or death. Anti-malarial drug effectiveness, a cornerstone for prevention and treatment, can be sub-optimal due to ever-emerging resistance, the need for frequent administration, and difficulties with compliance.

    In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). Scientific Reports, 5 March 2021.

    Editor Pick Malaria Therapeutic Antibodies WRAIR
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleHow Arctic Sea Ducks Develop Herd Immunity From Avian Cholera
    Next Article How CDC Global Experts Are Working to Eliminate Rubella

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.